Xi'an Faithful BioTech Co., Ltd. is selling Tadalafil Powder 99 Purity CAS 171596-29-5. Please feel free to contact us if you have any purchase needs.
Tadalafil Powder 99 Purity CAS 171596-29-5 is commonly used in adult men. Exposure to adjectives and other devices can increase the release of carbon monoxide, so this product can inhibit the increase in phosphodiesterase and improve cyclic guanosine monophosphate levels. If a patient is diagnosed with pulmonary hypertension, Tadalafil can also be used because it has a relatively broad range of effects. However, it must be used according to a doctor's instructions and not excessively. Doses exceeding 10 grams can cause a series of side effects. Men should wait 30 minutes before taking it, so that the product's effectiveness is not affected by their diet or daily routine. Patients with liver and kidney dysfunction should be careful to reduce their dosage appropriately.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Basic Properties Of Tadalafil: The Core Advantage Of A Long-Acting PDE5 Inhibitor
As a selective, reversible phosphodiesterase 5 (PDE5) inhibitor, Tadalafil holds a significant position in the andrology and cardiovascular fields due to its unique pharmacological properties. Its core advantage lies in its exceptionally long duration of action, with a half-life of up to 17.5 hours, far exceeding similar products. The effect persists for 24-36 hours after use, earning it the nickname "weekend pill." This feature significantly enhances flexibility and patient compliance.
II. Clinical Application Scenarios: Expanding from Men's Diseases to Multiple Fields
(I) Erectile Dysfunction (ED): Core Therapeutic Area
ED is Tadalafil's primary indication. Approximately 520 million people worldwide suffer from ED, with over 40% of those aged 40 and older. Clinical data show that Tadalafil's efficacy in treating ED reaches 70%-80%, significantly higher than the placebo group (approximately 20%). Compared to traditional medications, its advantages lie not only in its long-lasting effect but also in its unaffected by food intake-Tadalafil's absorption is independent of food, greatly enhancing its ease of use.
(II) Benign Prostatic Hyperplasia (BPH): A Cross-Disciplinary Breakthrough
In 2003, the US FDA approved Tadalafil for the treatment of BPH, becoming the first PDE5 inhibitor approved for both ED and BPH. BPH is a common disease in middle-aged and elderly men, affecting over 50% of men over 60 and up to 70% of those over 70. Tadalafil relaxes the smooth muscles of the prostate and bladder neck, improving urethral obstruction and relieving symptoms such as frequent urination, urgency, and dysuria.
(III) Pulmonary Arterial Hypertension (PAH): A Niche but Critical Indication
In 2009, Tadalafil was approved for the treatment of WHO Grade II and III PAH. PAH is a rare and fatal cardiovascular disease with a global incidence of approximately 15-50 per million people and an average survival of only 2-3 years. Tadalafil dilates pulmonary blood vessels, reduces pulmonary artery pressure, and improves right heart function, providing an important treatment option for patients.
III. Global Market Landscape: Competition and Development in Original Research
(I) Market Size: A Continuously Growing Billion-Dollar Market
The global tadalafil market has maintained an average annual growth rate of 8%-10% since 2010. By 2023, the market had exceeded US$8 billion and is projected to reach US$11 billion by 2028. Regionally, North America is the largest market, accounting for over 45%, followed by Europe (approximately 30%). Asia-Pacific is experiencing the fastest growth, with a compound annual growth rate exceeding 12%, primarily driven by demand from emerging markets such as China and India.
(II) Market Trends: From Standard Formulations to Innovative Dosage Forms
The current Tadalafil market exhibits two major trends: First, dosage form innovation. In addition to traditional tablets, formulations such as transdermal patches and oral fast-dissolving films are currently under development. Transdermal patches are slowly absorbed through the skin, avoiding the first-pass effect in the liver and making them suitable for patients with weak gastrointestinal function. Second, the development of combination formulations. For example, the combination formulation of Tadalafil and Dapoxetine (a drug for premature ejaculation) has been approved in countries such as India and South Korea. It can treat both ED and premature ejaculation, meeting the diverse needs of patients. These combination formulations are expected to become a new engine of future market growth.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
IV. R&D Progress and Technical Challenges: Breaking Through Existing Limitations
(I) New Indication Development: Expanding Therapeutic Frontiers
Currently, clinical research on Tadalafil is progressing in areas such as diabetes-related ED and female sexual dysfunction (FSD). The incidence of ED in diabetic patients is as high as 70%, and they respond poorly to traditional medications. Clinical data show that Tadalafil combined with insulin therapy can increase the efficacy rate in diabetic ED patients to over 65%, significantly higher than monotherapy. In the field of FSD, Tadalafil improves pelvic blood flow and has a modest effect on decreased libido and sexual arousal disorders. Phase II clinical trials have shown an efficacy rate of 40%, making it the first PDE5 inhibitor approved for the treatment of FSD.
(II) Technical Challenges: Bioavailability and Drug Resistance
Despite its significant advantages, Tadalafil still faces technical limitations: First, its bioavailability is low, reaching only approximately 25% after direct use, and there is significant inter-individual variability, requiring some patients to increase their dosage to achieve therapeutic efficacy. Second, long-term drug resistance is a concern. Approximately 10%-15% of patients experience decreased efficacy after long-term use. Current research suggests this is related to downregulation of PDE5 enzyme expression and abnormalities in the cGMP signaling pathway. To address this issue, researchers are developing combination formulations of PDE5 enzyme activators and Tadalafil to enhance efficacy and delay the development of drug resistance.
(III) Quality Control of Generic Drugs: Key to Consistency Evaluation
As the generic drug market expands, quality control becomes crucial. Tadalafil generics must undergo in vitro dissolution testing and in vivo bioequivalence (BE) testing to ensure consistency with the original drug. Currently, more than 20 companies in China have passed the Tadalafil consistency evaluation, with dissolution similarity exceeding 90% and a BE test pass rate exceeding 85%. However, some small companies still have problems such as insufficient raw material purity and substandard formulation processes, requiring strengthened supervision.
1. Do you have a problem whit delivery to my country?
A:We have warehouses in Europe, America and Australia. At the same time, if you are from Europe, the goods can be sent from Germany, and if you are from America or Canada, the goods can be sent from California.
2. How is the goods packed?
A:We usually send goods with disguise package outside and a double-layer sterile transparent bag inside.We have tried thousand of package methods, it looks serious and discreet.
3. When will you sent out the goods after successful payment?
A:Normally the order will be delivery within 3-7 days after the order confirmed, except the customized products.
4. How to proceed order?
A:Please Let me konw the product you are looking for,quantity and the destination country wihch help me to give you a right price;After you confirm all details of order, pay money in advance and give us Shipping address.We arrange the shipment at first time after receive payment and offer after-sales service after you receive parcel.
Conclusion
Over the next 5-10 years, the tadalafil industry will develop in three key areas: First, precision medicine, using genetic testing to screen for patients sensitive to tadalafil and enable personalized use. Currently, CYP3A4 gene polymorphisms have been found to be associated with tadalafil metabolism, and patients with specific genotypes can experience a 30% increase in drug efficacy. Second, combination therapy, combining tadalafil with androgen replacement therapy and stem cell therapy, is being used to treat refractory ED. Clinical studies have shown that combining tadalafil with testosterone replacement therapy can increase the efficacy rate in patients with refractory ED from 20% to 55%. Third, expansion into emerging markets. With economic development and improved medical standards in regions like Brazil and Southeast Asia, the ED diagnosis rate has increased from less than 20% to 40%, creating new growth opportunities for the tadalafil market. Emerging markets are expected to account for over 25% of the market by 2028.
As a representative long-acting PDE5 inhibitor, tadalafil has become a key drug in the andrology and cardiovascular fields due to its unique pharmacological advantages and extensive clinical application. Driven by both technological innovation and policy regulations, the industry will gradually transform from "scale expansion" to "high-quality development," providing safer and more effective treatment options for patients around the world while also bringing new development opportunities to companies.
As a provider of premium Tadalafil Powder 99 Purity CAS 171596-29-5, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Tadalafil Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.